| [1] |
Rottmann D, Snir OL, Wu X, et al. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy[J]. Mod Pathol, 2020, 33(1):118-127. doi: 10.1038/s41379-019-0358-x.
|
| [2] |
卢怡璇, 刘宗谕, 吴飞, 等. 原发性输卵管癌肉瘤的研究进展[J]. 中国妇幼保健, 2023, 38(23):4740-4743. doi: 10.19829/j.zgfybj.issn.1001-4411.2023.23.053.
|
| [3] |
Gauci M, Calleja-Agius J. Spotlight on Carcinosarcoma of the Ovary: A Scoping Review[J]. Acta Medica(Hradec Kralove), 2024, 67(1):1-11. doi: 10.14712/18059694.2024.13.
|
| [4] |
邢笑宇, 史惠惠, 邓学利, 等. 13例卵巢癌肉瘤临床特征分析及相关文献回顾[J]. 现代妇产科进展, 2024, 33(2):137-141. doi: 10.13283/j.cnki.xdfckjz.2024.02.008.
|
| [5] |
Xu J, Tu M. Single-cell transcriptomics reveals tumor landscape in ovarian carcinosarcoma[J]. J Zhejiang Univ Sci B, 2024, 25(8):686-699. doi: 10.1631/jzus.B2300407.
|
| [6] |
Ma Q, Ye S, Liu H, et al. HMGA2 promotes cancer metastasis by regulating epithelial-mesenchymal transition[J]. Front Oncol, 2024, 14:1320887. doi: 10.3389/fonc.2024.1320887.
|
| [7] |
Davidson B, Holth A, Lindemann K, et al. Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations[J]. Virchows Arch, 2024, 485(6):1053-1061. doi: 10.1007/s00428-024-03821-9.
|
| [8] |
Nakashima A, Maruyama Y, Saji H, et al. Bulky peritoneal carcinosarcoma with tiny high-grade serous carcinoma of the fallopian tube: a case report[J]. Int Cancer Conf J, 2021, 10(1):72-77. doi: 10.1007/s13691-020-00451-1.
|
| [9] |
Liang WW, Lin YN, Lee YN. Malignant mixed müllerian tumor of fallopian tube. Report of a case and review of literature[J]. Zhonghua Yi Xue Za Zhi(Taipei), 1990, 45(4):272-275.
|
| [10] |
Fu J. Management of a rare ovarian carcinosarcoma: A case report and literature review[J]. Exp Ther Med, 2022, 24(3):583. doi: 10.3892/etm.2022.11520.
pmid: 35949347
|
| [11] |
Ismail A, Choi S, Boussios S. Frontiers of Ovarian Carcinosarcoma[J]. Curr Treat Options Oncol, 2023, 24(12):1667-1682. doi: 10.1007/s11864-023-01138-4.
|
| [12] |
Li C, Li J, Huang Q, et al. Developing and validating a novel nomogram used a competing-risks model for predicting the prognosis of primary fallopian tube carcinoma: a retrospective study based on the SEER database[J]. Ann Transl Med, 2021, 9(5):378. doi: 10.21037/atm-20-5398.
pmid: 33842599
|
| [13] |
Karpathiou G, Chauleur C, Dal Col P, et al. FOXA1 Expression by Immunohistochemistry in Carcinosarcomas of the Endometrium and Ovary/Fallopian Tube[J]. Int J Gynecol Pathol, 2021, 40(6):611-616. doi: 10.1097/PGP.0000000000000772.
pmid: 33770058
|
| [14] |
Liang F, Shi Y, Chen Y, et al. Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: a series of 51 cases[J]. Front Oncol, 2024, 14:1427154. doi: 10.3389/fonc.2024.1427154.
|
| [15] |
Sumino M, Hashimoto H, Sato N, et al. Ovarian carcinosarcoma of heterologous type occurring in an endometriotic cyst with 3-year recurrence-free survival: a case report and literature review[J]. Int Cancer Conf J, 2025, 14(1):21-26. doi: 10.1007/s13691-024-00728-9.
|
| [16] |
张鹏闯, 胡丽娟, 吴涛, 等. 《2024.V1版卵巢癌包括输卵管癌和原发性腹膜癌》NCCN证据块指南解读[J]. 肿瘤预防与治疗, 2024, 37(5):372-384. doi: 10.3969/j.issn.1674-0904.2024.05.003.
|
| [17] |
Alwosaibai K, Aalmri S, Mashhour M, et al. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers[J]. BMC Cancer, 2023, 23(1):13. doi: 10.1186/s12885-022-10404-x.
pmid: 36604635
|
| [18] |
Nicoletti R, Lopez S, Bellone S, et al. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2[J]. Clin Exp Metastasis, 2015, 32(1):29-38. doi: 10.1007/s10585-014-9688-8.
|
| [19] |
Ho GY, Kyran EL, Bedo J, et al. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin[J]. Cancer Res, 2022, 82(23):4457-4473. doi: 10.1158/0008-5472.CAN-21-4012.
|